Novartis says the European Commission approved Diovan, its biggest selling drug, to treat children and adolescents with high blood pressure, a move likely to extend patent protection for the blockbuster med. Report
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments